Age-Related Macular Degeneration and Metformin

Kimberly Nguyen, MD

Objectives

- Understand the basics of Age Related Macular Degeneration (AMD)
- Understand the relationship between metformin use and AMD
- Counsel patients with AMD on the potential ocular effects of metformin use

Outline

- AMD: Definition, epidemiology, pathophysiology, management, prognosis
- Metformin: Mechanism, indications, adverse effects
- Clinical trials demonstrating the relationship between metformin and AMD
Age-Related Macular Degeneration (AMD) Definition

- Chronic progressive degenerative disorder of the macula due to age-related changes leading to loss of central vision
- Dry/nonexudative: small drusen → geographic atrophy
- Wet/exudative: Neovascularization

AMD Epidemiology

- Third most common cause of blindness worldwide
- Rare in pts under 55 yo
- More commonly in pts older than 75 years
- F>M
- Risk factors: light irides, age, smoking, hyperopia, hypertension, hypercholesterolemia, family history

AMD Pathophysiology

- RPE failure to process cellular debris
- Lipids deposited in Bruch’s membrane
- Drusen (lipid, amyloid, complements factors, cellular components)
- Thickening of Bruch’s, degeneration of collagen and elastin within Bruch’s, increased glycation end products, accumulation of lipids and cellular debris form barrier between choroid and retina → relative ischemia with subsequent CNV
AMD Management

- Dry AMD: AREDS2
  - Decrease progression to wet AMD
  - Smoking cessation
- Wet AMD:
  - Anti-VEGF: bevacizumab, aflibercept, ranibizumab

AREDS

- Objective: Reduce the risk of vision loss in intermediate/stage 3 to advanced/stage 4 nonexudative AMD
  - Intermediate/stage 3 = 1 large druse >= 125um, extensive soft intermediate drusen (63-142um) or nonsubfoveal GA
  - Advanced/stage 4 = vision loss due to neovascular AMD or subfoveal GA in one eye
  - AREDS formulation: VitC (500 mg), vitE (400 IU), betacarotene (15 mg), zinc (80 mg)
- Findings:
  - Intermediate or advanced AMD had 25% risk reduction for progression to more advanced stage of AMD and 19% reduction in mod vision loss (>= 3 lines) at 5 years
  - 23% reduction in progressing to advanced AMD at 10 years
  - No benefit for no AMD or early stage, no increased mortality

AREDS2

- Objective: Replaced beta carotene with lutein (10mg) and zeaxanthin (2 mg) and added omega 3
  - AREDS2: vitC, vitE, lutein, zeaxanthin, zinc; no betacarotene
- Findings
  - Similar visual outcomes as AREDS
  - Less risk of lung cancer in current and former smokers (beta carotene)
**AMD Prognosis**

- Risk of developing advanced AMD in one eye at 5 or 10 years
  - Presence of 1 or more large drusen (≥125μm) (1 point)
  - Presence of pigment abnormalities (1 point)
  - If no large drusen, presence of bilateral intermediate drusen (63-124μm)
  - Presence of neovascular AMD (2 points)

<table>
<thead>
<tr>
<th>Number of Risk Factor Points</th>
<th>5-Year Risk %</th>
<th>10-Year Risk %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.5</td>
<td>2</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>12</td>
<td>22</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>67</td>
</tr>
<tr>
<td>4</td>
<td>50</td>
<td>87</td>
</tr>
</tbody>
</table>

**Metformin Mechanism of Action**

- Primary site of action: mitochondria
- Inhibit hepatic gluconeogenesis
- Opposing glucagon mediated signaling in the liver
- Minor: increase glucose uptake in skeletal muscle

*Perneczky I, Korbonits M.*

**Metformin Indications**

- Diabetes mellitus type 2
Metformin Adverse Effects

- Nausea/vomiting
- GI upset
- Diarrhea
- Weakness
- Metallic taste
- Lactic acidosis (rare, most severe)

AMD and Metformin Studies

  - Objective: Determine whether metformin use is associated with reduced odds of developing of AMD
  - Methods
    - Case-control study
    - 55 years or older with new diagnosed AMD (cases) matched with control subjects
    - Exposure: dosage of metformin
  - Results
    - Metformin associated with reduced odds of developing AMD (OR 0.94, 95% CI 0.92-0.96)
    - Dose dependent; low to moderate doses of metformin showed the greatest potential benefit
    - Doses of more than 1080 g of metformin over 2 years did not have reduced odds of developing AMD
  - Conclusions
    - Metformin may be useful as a preventive therapy for AMD and provides the basis for potential prospective clinical trials

AMD and Metformin Studies

  - Objective: Systemic review and meta analysis to review beneficial associations between metformin and AMD
  - Methods
    - Systemic search of several databases for clinical studies between metformin and AMD (5 retrospective studies)
  - Results
    - Pts taking metformin were less likely to have AMD although statistical significance was not met (pooled adjusted OR = 0.80, 95% CI 0.54-1.05, I² = 98.8%)
  - Conclusions
    - Metformin may be associated with decreased risk of any AMD (although should be interpreted with caution because of the failure to meet statistical significance)
    - Limitations: small number of studies limited routine record data
AMD and Metformin Studies

  - Objectives: Evaluate the development of AMD in those taking metformin vs not taking the drug
  - Methods
    - Cross sectional retrospective study
    - N = 3120 diabetic pts >60 years old
  - Results
    - Those taking metformin were less likely to have age-related macular degeneration compared with those not taking the drug (OR 0.70, 95%CI 0.55-0.88)

AMD and Metformin Studies

  - Objectives: whether metformin is associated with a lower risk of subsequent AMD in patients with type 2 diabetes
  - Methods
    - Retrospective cohort study
    - Type 2 diabetics using metformin (N=45,524) vs type 2 diabetics not using metformin (N = 22,681)
  - Results
    - Metformin group had a significantly lower risk of AMD (adjusted HR = 0.54; 95% confidence interval [CI], 0.50-0.58)
  - Conclusions
    - Among patients with type 2 diabetes, those who use metformin are at a significantly lower risk of developing AMD relative to individuals who do not use metformin
    - Significantly lower AMD risk was found with a higher dose of metformin

AMD and Metformin Current Clinical Trials

- Title: Metformin for the minimization of Geographic Atrophy Progression in Patients with AMD
  - Objectives: The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD)
  - Treatment vs observation groups
    - Treatment group: Metformin daily for 18 months + standard ophthalmic care over 24 months
    - Observation group: standard ophthalmic care over 24 months
  - Testing: fundus photos, autofluorescence, OCT
  - Outcomes
    - Rate of change in area of geographic atrophy on imaging
    - BCVA
    - Systemic safety of metformin use (monitoring for adverse effects)
Conclusions

- AMD is a chronic progressive degenerative disorder of the macula due to age-related changes leading to loss of central vision.
- AREDS2 supplementation has been shown in clinical trials to decrease the risk of progression from nonexudative to exudative AMD.
- Metformin is a widely used oral medication for the management of diabetes mellitus type 2.
- Metformin use may be associated with a decreased risk of developing AMD.
- Further studies are required to evaluate the efficacy of metformin use and the development of AMD.

References